{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T06:00:05Z","timestamp":1720936805459},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejcancer.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ejca.2015.02.004","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T14:50:43Z","timestamp":1424875843000},"page":"751-757","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis"],"prefix":"10.1016","volume":"51","author":[{"given":"Yudi","family":"Pawitan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin E.","family":"Smedby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamila","family":"Czene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2015.02.004_b0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effects of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trails","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2015.02.004_b0010","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1101\/gad.223339.113","article-title":"Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos","volume":"27","author":"Briso","year":"2013","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2015.02.004_b0015","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/jgh.12435","article-title":"Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer","volume":"29","author":"Koh","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2015.02.004_b0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ijc.24757","article-title":"Cyclooxygenase-2 inhibition inhibits PI3K\/AKT kinase activity in epithelial ovarian cancer","volume":"126","author":"Uddin","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2015.02.004_b0025","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"NEJM"},{"key":"10.1016\/j.ejca.2015.02.004_b0030","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing Rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial","volume":"28","author":"Midgley","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.02.004_b0035","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","volume":"31","author":"Domingo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2015.02.004_b0040","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/bjc.2013.411","article-title":"Low-dose aspirin use and cancer characteristics: a population-based cohort study","volume":"109","author":"Jonsson","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2015.02.004_b0045","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.bjp.0706013","article-title":"Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation","volume":"143","author":"Jurasz","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2015.02.004_b0050","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jcp.24539","article-title":"Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer","volume":"229","author":"Sharma","year":"2013","journal-title":"J Cell Phys"},{"key":"10.1016\/j.ejca.2015.02.004_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/02841860802247664","article-title":"The completeness of the Swedish Cancer Register: a sample survey for year 1998","volume":"48","author":"Barlow","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2015.02.004_b0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register \u2013 opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.ejca.2015.02.004_b0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamainternmed.2014.511","article-title":"Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer","volume":"174","author":"Reimers","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejca.2015.02.004_b0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/gut.2004.047100","article-title":"Recent advances in basic science prostaglandin and cancer","volume":"55","author":"Wang","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2015.02.004_b0085","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin inhibits mTOR signaling, activates AMP-Activated Protein Kinase, and induces autophagy in colorectal cancer cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejca.2015.02.004_b0090","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"NEJM"},{"issue":"2","key":"10.1016\/j.ejca.2015.02.004_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccr.2011.12.026","article-title":"VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium","volume":"21","author":"Karnezis","year":"2012","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915001306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804915001306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T21:54:13Z","timestamp":1537826053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804915001306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0959804915001306"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2015.02.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct effects of anti-inflammatory and anti-thrombotic drugs on cancer characteristics at diagnosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2015.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}